MaxCyte (MXCT) News Today $4.94 +0.19 (+4.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period MaxCyte (NASDAQ: MXCT) Announces Preliminary Financial Results for Q4 and FY 2024ROCKVILLE, MD, January 13, 2025 -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a prominent cell-engineering company specializing in platform technologies for advancing the January 21 at 2:05 AM | americanbankingnews.comMaxCyte, Inc. (NASDAQ:MXCT) Stake Boosted by Barclays PLCBarclays PLC boosted its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 329.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 165,765 shares of the company's stock after buying an additional 127January 17, 2025 | marketbeat.comBlackRock Increases Stake in MaxCyte, Inc.January 15, 2025 | tipranks.comMaxCyte (MXCT) Receives a Buy from Craig-HallumJanuary 14, 2025 | markets.businessinsider.comDavid I. Sandoval Sells 4,466 Shares of MaxCyte, Inc. (NASDAQ:MXCT) StockMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) General Counsel David I. Sandoval sold 4,466 shares of the firm's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $4.54, for a total transaction of $20,275.64. Following the completion of the sale, the general counsel now owns 41,447 shares in the company, valued at approximately $188,169.38. The trade was a 9.73 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.January 14, 2025 | marketbeat.comMaxCyte (NASDAQ:MXCT) Shares Up 8.2% - Here's WhyMaxCyte (NASDAQ:MXCT) Trading Up 8.2% - Should You Buy?January 13, 2025 | marketbeat.comMaxCyte, Inc: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial ResultsJanuary 13, 2025 | finanznachrichten.deMaxCyte Preliminary Q4 Core Revenue ImprovesJanuary 13, 2025 | markets.businessinsider.comMaxCyte, Inc. Reports Preliminary Financial Results for Fourth Quarter and Full Year 2024January 13, 2025 | quiverquant.comMaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial ResultsJanuary 13, 2025 | globenewswire.comMaxCyte Expands Common Stock Issuance to 105.7 Million SharesJanuary 2, 2025 | tipranks.comBarclays PLC Grows Holdings in MaxCyte, Inc. (NASDAQ:MXCT)Barclays PLC raised its position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 329.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 165,765 shares of the company's stock after purchasiJanuary 2, 2025 | marketbeat.comInsider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 3,000 Shares of StockDecember 31, 2024 | insidertrades.comMaxCyte, Inc. (NASDAQ:MXCT) Director Sells $12,030.00 in StockMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 3,000 shares of the stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $4.01, for a total value of $12,030.00. Following the transaction, the director now owns 141,950 shares in the company, valued at $569,219.50. This trade represents a 2.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.December 30, 2024 | marketbeat.comMaxCyte Announces Retirement of Board Member Art MandellDecember 23, 2024 | globenewswire.comFmr LLC Sells 437,232 Shares of MaxCyte, Inc. (NASDAQ:MXCT)Fmr LLC lowered its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 12.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,982,549 shares of the company's stock after sellDecember 12, 2024 | marketbeat.comMaxCyte, Inc. Announces Change in Major Holdings by BlackRockDecember 10, 2024 | tipranks.comMaxCyte raises FY24 core business revenue view to 6%-8% from flat to up 5%December 10, 2024 | markets.businessinsider.comMaxCyte Streamlines Workforce and Boosts Revenue OutlookDecember 9, 2024 | tipranks.comMaxCyte Announces Streamlined Operations and Raises 2024 Revenue GuidanceDecember 9, 2024 | globenewswire.comMaxCyte, Inc. (NASDAQ:MXCT) Shares Purchased by ArrowMark Colorado Holdings LLCArrowMark Colorado Holdings LLC raised its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 13.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,394,947 shares of the company's stock after buying an adDecember 3, 2024 | marketbeat.comMudita Advisors LLP Acquires 167,101 Shares of MaxCyte, Inc. (NASDAQ:MXCT)Mudita Advisors LLP lifted its holdings in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 5.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,153,441 shares of the company's stock after purchasing an additional 167,101 shares during theNovember 27, 2024 | marketbeat.comMaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based TherapeuticsNovember 13, 2024 | globenewswire.comMaxCyte’s Strong Performance and Growth Potential Justifies Buy Rating by Mark MassaroNovember 12, 2024 | markets.businessinsider.comFY2024 Earnings Forecast for MaxCyte Issued By William BlairMaxCyte, Inc. (NASDAQ:MXCT - Free Report) - William Blair lifted their FY2024 earnings estimates for MaxCyte in a research report issued to clients and investors on Thursday, November 7th. William Blair analyst M. Larew now expects that the company will earn ($0.43) per share for the year, up froNovember 11, 2024 | marketbeat.comMaxCyte Weighs Delisting from AIM to Prioritize Nasdaq: Potential Benefits and Risks AheadNovember 8, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on MaxCyte (MXCT)November 7, 2024 | markets.businessinsider.comMaxCyte’s Q3 Performance and Strategic Initiatives Signal Strong Growth Potential and Investment OpportunityNovember 7, 2024 | markets.businessinsider.comMaxCyte, Inc. (MXCT) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comMaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 GuidanceNovember 6, 2024 | globenewswire.comMaxCyte Expands Stock Capital with New IssuanceNovember 4, 2024 | markets.businessinsider.comMaxCyte’s Insider Stock Activity in FocusOctober 31, 2024 | markets.businessinsider.comMaxCyte to Participate in Two Upcoming Investor ConferencesOctober 31, 2024 | globenewswire.comMaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 SharesOctober 31, 2024 | insidertrades.comMaxCyte (MXCT) Scheduled to Post Quarterly Earnings on WednesdayMaxCyte (NASDAQ:MXCT) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=635048)October 30, 2024 | marketbeat.comMaxCyte adds biotech veteran Collins to boardOctober 17, 2024 | investing.comMaxCyte Appoints Cynthia Collins to its Board of DirectorsOctober 15, 2024 | globenewswire.comMaxCyte, Inc: MaxCyte Appoints Ali Soleymannezhad as Chief Commercial OfficerOctober 12, 2024 | finanznachrichten.deMaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024October 11, 2024 | globenewswire.comMaxCyte Appoints Ali Soleymannezhad as Chief Commercial OfficerOctober 10, 2024 | globenewswire.comMillennium Management LLC Sells 993,093 Shares of MaxCyte, Inc. (NASDAQ:MXCT)Millennium Management LLC lowered its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 16.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,177,953 shares of the company's stock after selling 993,093 sharOctober 5, 2024 | marketbeat.comMaxcyte: Reaching Financial Inflection With CASGEVY Ramp UpOctober 4, 2024 | seekingalpha.comStanley C. Erck Sells 21,607 Shares of MaxCyte, Inc. (NASDAQ:MXCT) StockOctober 3, 2024 | insidertrades.comMassachusetts Financial Services Co. MA Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT)Massachusetts Financial Services Co. MA cut its position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 80.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 499,635 shares of the company's stock after selling 2,025,September 23, 2024 | marketbeat.comMaxCyte, Inc: MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic DiseasesSeptember 16, 2024 | finanznachrichten.deMaxCyte touts strategic platform license deal with Kamau TherapeuticsSeptember 16, 2024 | lse.co.ukMaxCyte In Deal With Kamau Therapeutics To Boost Cell Therapy Development For Genetic DiseasesSeptember 16, 2024 | markets.businessinsider.comMaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic DiseasesSeptember 16, 2024 | globenewswire.comMaxCyte, Inc. (NASDAQ:MXCT) Director Sells $118,174.99 in StockSeptember 7, 2024 | insidertrades.comInsider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 29,767 Shares of StockMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director Stanley C. Erck sold 29,767 shares of the company's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.97, for a total value of $118,174.99. Following the sale, the director now owns 269,118 shares of the company's stock, valued at $1,068,398.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.September 5, 2024 | marketbeat.com Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address MXCT Media Mentions By Week MXCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MXCT News Sentiment▼0.710.49▲Average Medical News Sentiment MXCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MXCT Articles This Week▼62▲MXCT Articles Average Week Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Premier News Criteo News EVERTEC News LiveRamp News Donnelley Financial Solutions News Astrana Health News Applied Digital News Xometry News NeoGenomics News GoodRx News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MXCT) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MXCT Stock Alerts